Results from the Phase III WAYPOINT trial in patients with chronic rhinosinusitis with nasal polyps showed that AstraZeneca (AZN) and ...

Researchers emphasized the potential of Tezspire to offer a new treatment option that addresses the multiple inflammatory ...

AstraZeneca Plc (NASDAQ:AZN) and Amgen Inc (NASDAQ:AMGN) released topline data from the Phase 3 WAYPOINT trial of Tezspire ...

Amgen (AMGN) and AstraZeneca (AZN) announced top-line results from the Phase 3 WAYPOINT trial in patients with chronic rhinosinusitis with ...

"Chronic rhinosinusitis with nasal polyps negatively impact patients’ daily lives with obstructions leading to disturbances in smell, taste and sleep as well as pain and fatigue. The impressive data ...

Amgen (NASDAQ:AMGN) and AstraZeneca (NASDAQ:AZN) announced Friday that their FDA-approved asthma therapy Tezspire reached ...

(Alliance News) - AstraZeneca PLC on Friday said it received positive results from a trial of Tezspire as a treatment for chronic rhinosinusitis with nasal polyps.

Chronic rhinosinusitis with nasal polyps can lead to obstructions in the nasal passage, resulting in disturbances in smell, ...

Common symptoms include nasal congestion, reduced sense of smell ... factor in their formation,” Dr Pirzada explained. This ...

According to the Centers for Disease Control and Prevention (CDC), allergies are now the sixth leading cause of chronic ...

A few allergy seasons back, she thought her seasonal congestion might ... while trying to quit the nasal decongestants,” Wang says. “We may also recommend other treatments, such as drugs ...